

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 AUGUST 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

<u>Item</u>	<u>PBAC Advice</u>
Alirocumab	<p>The sponsor requested the delisting of Praluent[®] (alirocumab) from the Pharmaceutical Benefits Scheme (PBS).</p> <p>The Pharmaceutical Benefits Advisory Committee (PBAC) noted the low number of services in the last financial year and that there are suitable alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Fluorometholone	<p>The sponsor requested the delisting of FML Liquifilm[®] (fluorometholone) from the PBS.</p> <p>The PBAC noted the high number of services in the last financial year and that it has potential clinical benefits compared to alternatives. The PBAC advised the delisting of this product may result in an unmet clinical need.</p>
Glucose indicator-urine	<p>The sponsor requested the delisting of Diastix[®] (glucose indicator urine diagnostic strips) from the PBS.</p> <p>The PBAC noted the low number of services in the last financial year and that there is an alternative on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>
Oxprenolol	<p>The sponsor requested the delisting of Corbeton 40 (oxprenolol hydrochloride) from the PBS.</p> <p>The PBAC noted the low number of services in the last financial year. The PBAC advised the delisting of this product would not result in an unmet clinical need.</p>

Tafluprost

The sponsor requested the delisting of Saflutan[®] (tafluprost) from the PBS.

The PBAC noted the moderate number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.

Vanessa McMahon
Director, PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
19 July 2024